New injection shows promise for long-term prevention of rare swelling disorder
NCT ID NCT04739059
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the long-term safety and effectiveness of garadacimab, a monthly injection, for preventing attacks of hereditary angioedema (HAE) — a rare condition causing severe swelling. 171 people aged 12 and older who had frequent HAE attacks took part. The goal was to see if the drug could safely reduce attack rates over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
garadacimab (a monoclonal antibody injection)
What this could lead to
If successful, this could provide a long-term preventive option to reduce swelling attacks in people with hereditary angioedema.
What could go wrong
This is an open-label study without a placebo group, so results may be less reliable. Side effects or lack of lasting benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AARA Research Center
Dallas, Texas, 75231, United States
-
Allergy & Asthma Clinical Research
Walnut Creek, California, 94598, United States
-
Amsterdam UMC, location AMC
Amsterdam, 1105, Netherlands
-
Auckland City Hospital
Grafton, Auckland, 1023, New Zealand
-
Barzilai University Medical Center
Ashkelon, 7830604, Israel
-
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio, 45236, United States
-
Campbelltown Hospital / Western Sydney University
Campbelltown, New South Wales, 2560, Australia
-
Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
-
Clinical Research Center of Alabama
Birmingham, Alabama, 35209, United States
-
Clover Hospital
Kanagawa, Kugenumaishigami, Fujisawa-shi, 251-0025, Japan
-
Donald S. Levy M.D.
Orange, California, 92868, United States
-
Fiona Stanley Hospital, Department of Clinical Immunology
Murdoch, Western Australia, 6150, Australia
-
Gordon Sussman Clinical Research
Toronto, Ontario, M3B 3S6, Canada
-
HZRM Haemophilie Zentrum Rhein Main GmbH
Mörfelden-Walldorf, 64546, Germany
-
Hospital Gregorio Marañón, Servicio de Alergia
Madrid, 28007, Spain
-
Hospital Universitari General de La Vall d'Hebron
Barcelona, 8035, Spain
-
Institute for Asthma and Allergy PC
Chevy Chase, Maryland, 20815, United States
-
Johannes Gutenberg-Universität KöR, Hautklinik und Poliklinik der Universitätsmedizin, Clinical Research Center
Mainz, 55131, Germany
-
Juntendo University Hospital
Tokyo, Hongo Bunkyo-ku, 113-8431, Japan
-
Koga Community Hospital
Shizuoka, Daikakuji Yaizu-shi, 425-0088, Japan
-
Little Rock Allergy & Asthma Clinic
Little Rock, Arkansas, 72205, United States
-
Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital
Miyakojima-ku, Osaka-shi, 534-0021, Japan
-
McMaster University
Hamilton, Ontario, L8N 3Z5, Canada
-
Medical Research of Arizona
Scottsdale, Arizona, 85251, United States
-
Mie University Hospital
Mie, Edobashi, Tsu-shi, Edobashi, Tsu-shi, Japan
-
Montreal Clinical Research Institute
Montreal, Quebec, H2W 1R7, Canada
-
NRC Institute of Immunology FMBA Russia
Moscow, 115522, Russia
-
National Hospital Organization Disaster Medical Center
Tokyo, Midoricho, Tachikawa-shi, 190-0014, Japan
-
Ottawa Allergy Research Corp
Ottawa, Ontario, K1H 1E4, Canada
-
PennState Health Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
-
Raffi Tachdjian MD, Inc.
Santa Monica, California, 90404, United States
-
Research Solutions of Arizona
Litchfield Park, Arizona, 85340, United States
-
Saga University Hospital
Saga, Nebeshima, Saga-shi, 849-8501, Japan
-
Saitama Medical Center
Saitama, Kamoda Kawagoe-shi, 350-8550, Japan
-
Saiyu Soka Hospital
Saitama, Matsubara Soka-shi, 340-0041, Japan
-
Semmelweis Egyetem Altalanos Orvostudományi Kar Belgyógyászati és Hematológiai Klinika
Budapest, 1088, Hungary
-
St. Marianna University School of Medicine Hospital
Kanagawa, Kawasaki-shi, 216-8511, Japan
-
Taichung Veterans General Hospital
Taichung, 407, Taiwan
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
-
The University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong
-
University Hospital Motol
Prague, 150 06, Czechia
-
University hospital St. Anna Ustav klinicke imunologie a alergologie, Fakultní nemocnice u sv. Anny v Brně
Brno, 65691, Czechia
-
University of Alberta - Research Transition Facility
Edmonton, Alberta, T6G 2B7, Canada
-
Universitätsklinikum Frankfurt
Frankfurt, 60590, Germany